Table 1. Summary of metastatic and invasive patient-derived cancers.
Nineteen patient-derived breast cancer samples were used in this study. Primary invasive cancer samples are highlighted in grey. Tumour histology and grade for metastatic samples (Asc and PE) relates to the primary cancer. Samples with hyphenated numbers (e.g. BB3RC46-1 and BB3RC46-2) were obtained from the same patient at different time points. Metastatic fluid IL-8 levels were measured following removal of cellular matter using an ELISA. Asc ascites, B bone, Br brain, CT chemotherapy, duod duodenum, ER oestrogen receptor, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, Lv liver, Lu Lung, MFE mammosphere forming efficiency, NA not applicable, Neg negative, Neo neoadjuvant, NK not known, Panc pancreas, PE pleural effusion, Pos positive, PR progesterone receptor, T Traztuzumab, UA unavailable.
| Sample | Sample origin |
Tumour histology |
Grade | ER status |
PR status |
HER2 status |
Sites of metastases |
Medical treatment |
MFE (%) |
Metastatic fluid IL-8 level (pg/ml) |
|---|---|---|---|---|---|---|---|---|---|---|
| BB3RC36-1 | PE | IDC | 2 | Pos | Pos | Neg | Li and Lu | ET | 1.73 | UA |
| BB3RC36-2 | PE | IDC | 2 | Pos | Pos | Neg | Li and Lu | ET | 1.43 | UA |
| BB3RC38 | Asc | IDC | 3 | Neg | Neg | Neg | B, Lv and Lu | CT | 0.47 | 42.6 |
| BB3RC39 | PE | IDC | 3 | Neg | Neg | Neg | B, Br and Li | CT | 1.95 | 201.1 |
| BB3RC40 | Asc | IDC | 3 | Pos | Pos | Neg | Li | CT, ET | 0.25 | UA |
| BB3RC41 | Asc | IDC | 3 | Pos | Pos | Neg | Li | CT, ET | 1.20 | 135.9 |
| BB3RC42 | PE | IDC | 3 | Pos | Neg | Neg | Lu | CT, ET | 0.27 | 25.2 |
| BB3RC43-1 | Asc | IDC | 3 | Pos | Pos | Pos | Lv and Lu | CT, ET, T | 0.98 | 106.8 |
| BB3RC43-2 | Asc | IDC | 3 | Pos | Pos | Pos | Lv and Lu | CT, ET, T | 0.81 | UA |
| BB3RC43-3 | Asc | IDC | 3 | Pos | Pos | Pos | Li | CT, ET, T | 0.57 | UA |
| BB3RC47 | Asc | IDC | 3 | Pos | Neg | Neg | Li | CT, ET | 0.45 | 54.0 |
| BB3RC48 | Asc | ILC | 2 | Pos | Pos | Neg | Li and Lu | ET | 1.32 | 38.2 |
| BB3RC51 | PE | IDC | 2 | Pos | Pos | Neg | Panc and duod | CT, ET | 1.50 | 94.3 |
| BB3RC53 | Asc | IDC | 2 | Pos | Pos | NK | B, Li | CT, ET | 1.0 | 50.1 |
| BB3RC54 | PE | IDC | 3 | Pos | Pos | NK | B, Li, Lu | CT, ET | 1.51 | 45.1 |
| BB2RC12 | IDC | IDC | 3 | Pos | Neg | Pos | None | Neo CT and T |
0.98 | NA |
| BB2RC13 | IDC | IDC | 3 | Neg | Neg | Neg | None | None | 2.71 | NA |
| BB2RC14 | IDC | IDC | 3 | Neg | Neg | Pos | None | Neo CT and T |
0.30 | NA |
| BB2RC15 | IDC | IDC | 3 | Neg | Neg | Pos | None | Neo CT and T |
1.95 | NA |